康复新液联合双歧杆菌三联活菌胶囊对溃疡性结肠炎患者血清LPO、SOD水平及生活质量的影响

Therapeutic effect of Kangfuxin Liquid combined with Bifidobacterium triple viable capsule in patients with ulcerative colitis

摘要:

目的 探讨康复新液联合双歧杆菌三联活菌胶囊对溃疡性结肠炎患者血清脂质过氧化物（LPO）、超氧化物歧化酶（SOD）水平及生活质量的影响。方法 选取2015年1月—2017年3月河北省中医院129例溃疡性结肠炎患者，依据随机双盲法分为研究组、对照A组及对照B组，各43例。对照A组予以康复新液治疗，对照B组予以双歧杆菌三联活菌胶囊治疗，研究组予以康复新液联合双歧杆菌三联活菌胶囊治疗。观察统计3组治疗效果、药物不良反应，并对治疗前后3组血清LPO、SOD水平及生活质量变化情况进行比较。结果 研究组治疗总有效率与对照A、B组比较，差异有统计学意义（P?<0.05），研究组高于对照A、B组。治疗后，3组血清LPO、SOD水平、生活质量评分比较，差异有统计学意义（P?<0.05）；研究组血清LPO水平低于对照A、B组。血清SOD水平及生活质量评分均高于对照A、B组；治疗后，研究组血清LPO、SOD水平较治疗前均下降，生活质量评分均升高（P?<0.05）；对照A、B两组血清LPO、SOD水平、生活质量评分比较，差异无统计学意义（P?>0.05）。3组治疗期间药物不良反应发生率比较，差异无统计学意义（P?>0.05）。结论 对溃疡性结肠炎患者采用康复新液联合双歧杆菌三联活菌胶囊治疗，可有效降低血清LPO水平，提高血清SOD水平，改善患者生活质量，提高治疗效果，且安全性较高。

Abstract:

Objective To investigate therapeutic effect of Kangfuxin Liquid combined with Bifidobacterium triple viable capsule in patients with ulcerative colitis. Methods A total of 129 patients with ulcerative colitis who were admitted in our hospital from January 2015 to March 2017 were selected. They were divided into study group, control group A, and control group B (n?=?43). Patients in control group A was treated with Kangxinxin liquid, patients in group B was treated with Bifidobacterium triple live vitality capsule, and patients in study group was treated with Kangfuxin liqud combined with Bifidobacterium triple live capsule. The therapeutic effects and adverse reactions of the three groups were observed. Levels of serum LPO and SOD as well as quality of life were obtained. Results The total effective rate of the study group was increased significantly when compared with control group A and control group B (P??0.05). There was no significant difference in incidence rates of nausea, acid reflux, rash, abdominal discomfort in the three groups (P?>?0.05). Conclusions The combination of Kangfuxin liquid and Bifidobacterium triple live mushroom capsules can significantly improve the quality of life of patients probably through modulating LPO/SOD signaling pathway.